Factors that determine whether a patient receives completion axillary lymph node dissection after a positive sentinel lymph node biopsy for breast cancer in British Columbia.
Identifieur interne : 002594 ( PubMed/Corpus ); précédent : 002593; suivant : 002595Factors that determine whether a patient receives completion axillary lymph node dissection after a positive sentinel lymph node biopsy for breast cancer in British Columbia.
Auteurs : Nava Aslani ; Todd Swanson ; Hagen Kennecke ; Ryan Woods ; Noelle DavisSource :
- Canadian journal of surgery. Journal canadien de chirurgie [ 1488-2310 ] ; 2011.
English descriptors
- KwdEn :
- Aged, Axilla, Breast Neoplasms (pathology), Breast Neoplasms (surgery), British Columbia, Female, Humans, Lymph Node Excision, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local (epidemiology), Neoplasm Staging, Patient Selection, Retrospective Studies, Sentinel Lymph Node Biopsy, Treatment Outcome.
- MESH :
- geographic : British Columbia.
- epidemiology : Neoplasm Recurrence, Local.
- pathology : Breast Neoplasms.
- surgery : Breast Neoplasms.
- Aged, Axilla, Female, Humans, Lymph Node Excision, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Patient Selection, Retrospective Studies, Sentinel Lymph Node Biopsy, Treatment Outcome.
Abstract
Completion axillary lymph node dissection (CALND) is recommended in the setting of positive sentinel lymph node biopsy (SLNB) but is associated with a higher rate of postoperative complications. In this study, the characteristics and outcomes of patients who did and did not have CALND are compared.
DOI: 10.1503/cjs.007810
PubMed: 21651836
Links to Exploration step
pubmed:21651836Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Factors that determine whether a patient receives completion axillary lymph node dissection after a positive sentinel lymph node biopsy for breast cancer in British Columbia.</title>
<author><name sortKey="Aslani, Nava" sort="Aslani, Nava" uniqKey="Aslani N" first="Nava" last="Aslani">Nava Aslani</name>
<affiliation><nlm:affiliation>The General Surgery Residency Program, University of British Columbia, Vancouver, BC.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Swanson, Todd" sort="Swanson, Todd" uniqKey="Swanson T" first="Todd" last="Swanson">Todd Swanson</name>
</author>
<author><name sortKey="Kennecke, Hagen" sort="Kennecke, Hagen" uniqKey="Kennecke H" first="Hagen" last="Kennecke">Hagen Kennecke</name>
</author>
<author><name sortKey="Woods, Ryan" sort="Woods, Ryan" uniqKey="Woods R" first="Ryan" last="Woods">Ryan Woods</name>
</author>
<author><name sortKey="Davis, Noelle" sort="Davis, Noelle" uniqKey="Davis N" first="Noelle" last="Davis">Noelle Davis</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21651836</idno>
<idno type="pmid">21651836</idno>
<idno type="doi">10.1503/cjs.007810</idno>
<idno type="wicri:Area/PubMed/Corpus">002594</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002594</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Factors that determine whether a patient receives completion axillary lymph node dissection after a positive sentinel lymph node biopsy for breast cancer in British Columbia.</title>
<author><name sortKey="Aslani, Nava" sort="Aslani, Nava" uniqKey="Aslani N" first="Nava" last="Aslani">Nava Aslani</name>
<affiliation><nlm:affiliation>The General Surgery Residency Program, University of British Columbia, Vancouver, BC.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Swanson, Todd" sort="Swanson, Todd" uniqKey="Swanson T" first="Todd" last="Swanson">Todd Swanson</name>
</author>
<author><name sortKey="Kennecke, Hagen" sort="Kennecke, Hagen" uniqKey="Kennecke H" first="Hagen" last="Kennecke">Hagen Kennecke</name>
</author>
<author><name sortKey="Woods, Ryan" sort="Woods, Ryan" uniqKey="Woods R" first="Ryan" last="Woods">Ryan Woods</name>
</author>
<author><name sortKey="Davis, Noelle" sort="Davis, Noelle" uniqKey="Davis N" first="Noelle" last="Davis">Noelle Davis</name>
</author>
</analytic>
<series><title level="j">Canadian journal of surgery. Journal canadien de chirurgie</title>
<idno type="eISSN">1488-2310</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Axilla</term>
<term>Breast Neoplasms (pathology)</term>
<term>Breast Neoplasms (surgery)</term>
<term>British Columbia</term>
<term>Female</term>
<term>Humans</term>
<term>Lymph Node Excision</term>
<term>Middle Aged</term>
<term>Neoplasm Invasiveness</term>
<term>Neoplasm Recurrence, Local (epidemiology)</term>
<term>Neoplasm Staging</term>
<term>Patient Selection</term>
<term>Retrospective Studies</term>
<term>Sentinel Lymph Node Biopsy</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>British Columbia</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Neoplasm Recurrence, Local</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Axilla</term>
<term>Female</term>
<term>Humans</term>
<term>Lymph Node Excision</term>
<term>Middle Aged</term>
<term>Neoplasm Invasiveness</term>
<term>Neoplasm Staging</term>
<term>Patient Selection</term>
<term>Retrospective Studies</term>
<term>Sentinel Lymph Node Biopsy</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Completion axillary lymph node dissection (CALND) is recommended in the setting of positive sentinel lymph node biopsy (SLNB) but is associated with a higher rate of postoperative complications. In this study, the characteristics and outcomes of patients who did and did not have CALND are compared.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21651836</PMID>
<DateCreated><Year>2011</Year>
<Month>07</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted><Year>2011</Year>
<Month>10</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>02</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1488-2310</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>54</Volume>
<Issue>4</Issue>
<PubDate><Year>2011</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Canadian journal of surgery. Journal canadien de chirurgie</Title>
<ISOAbbreviation>Can J Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Factors that determine whether a patient receives completion axillary lymph node dissection after a positive sentinel lymph node biopsy for breast cancer in British Columbia.</ArticleTitle>
<Pagination><MedlinePgn>237-42</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1503/cjs.007810</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Completion axillary lymph node dissection (CALND) is recommended in the setting of positive sentinel lymph node biopsy (SLNB) but is associated with a higher rate of postoperative complications. In this study, the characteristics and outcomes of patients who did and did not have CALND are compared.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We identified all patients with breast cancer with positive sentinel lymph nodes (SLNs) who did not have concurrent CALND from 2003 to 2006 using a prospectively collected database (British Columbia Cancer Breast Outcomes database) and retrospective chart review. Patient and tumour characteristics were compared between those who received CALND and those who did not.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 185 patients with positive SLNs identified by SLNB, 90 had a CALND and 95 had no further surgical therapy. Patients who did not receive CALND had more sentinel nodes removed (p < 0.001), a lower percentage of positive SLNs (p < 0.001) and lower pathologic N stage (p = 0.044) than those who did receive CALND. The size of the breast lesion, size of the largest SLN deposit, estrogen receptor status, grade, lymphovascular invasion, histology and multifocality were not significantly different between groups. Sixty-two percent of women who did not have CALND received radiation to the axilla. Postoperative complication rates (including lymphedema) were higher in the CALND group (21%) compared with the SLNB group (7%). The rates of locoregional recurrence (1% in both groups) and systemic metastases (6% in the CALND group v. 8% in the SLNB group) were similar at 36 months' follow-up.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Compared with women who had CALND, women who did not receive CALND had on average a lower N stage with 3 or more SLNs removed and less than 50% node positivity. Most of these women received radiation therapy to the axilla and had comparable recurrence rates to those who had CALND.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aslani</LastName>
<ForeName>Nava</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>The General Surgery Residency Program, University of British Columbia, Vancouver, BC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Swanson</LastName>
<ForeName>Todd</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kennecke</LastName>
<ForeName>Hagen</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Woods</LastName>
<ForeName>Ryan</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Davis</LastName>
<ForeName>Noelle</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Canada</Country>
<MedlineTA>Can J Surg</MedlineTA>
<NlmUniqueID>0372715</NlmUniqueID>
<ISSNLinking>0008-428X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2001 Oct;182(4):365-8</RefSource>
<PMID Version="1">11720672</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Jun 20;27(18):2946-53</RefSource>
<PMID Version="1">19364968</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2003 Aug 7;349(6):546-53</RefSource>
<PMID Version="1">12904519</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2003 Dec;10(10):1140-51</RefSource>
<PMID Version="1">14654469</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2004 Jan 1;22(1):97-101</RefSource>
<PMID Version="1">14701770</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Oct 20;23(30):7703-20</RefSource>
<PMID Version="1">16157938</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2006 Jan 1;106(1):4-16</RefSource>
<PMID Version="1">16329134</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2006 Jan;13(1):36-44</RefSource>
<PMID Version="1">16378156</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2006 Jan 20;24(3):337-44</RefSource>
<PMID Version="1">16344321</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2006 Jun 1;93(7):550-8</RefSource>
<PMID Version="1">16705723</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Surg. 2006 Sep;141(9):867-72; discussion 872-4</RefSource>
<PMID Version="1">16983030</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg. 2007 Mar;245(3):462-8</RefSource>
<PMID Version="1">17435554</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 Aug 15;110(4):723-30</RefSource>
<PMID Version="1">17587208</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Aug 20;25(24):3657-63</RefSource>
<PMID Version="1">17485711</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 2008;47(2):232-8</RefSource>
<PMID Version="1">17924207</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2008 Sep;15(9):2562-7</RefSource>
<PMID Version="1">18618183</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Surg. 2003 May;138(5):482-7; discussion 487-8</RefSource>
<PMID Version="1">12742949</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001365" MajorTopicYN="N">Axilla</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001955" MajorTopicYN="N" Type="Geographic">British Columbia</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008197" MajorTopicYN="Y">Lymph Node Excision</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D021701" MajorTopicYN="N">Sentinel Lymph Node Biopsy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3191897</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>6</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>6</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>10</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21651836</ArticleId>
<ArticleId IdType="pii">10.1503/cjs.007810</ArticleId>
<ArticleId IdType="doi">10.1503/cjs.007810</ArticleId>
<ArticleId IdType="pmc">PMC3191897</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002594 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002594 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:21651836 |texte= Factors that determine whether a patient receives completion axillary lymph node dissection after a positive sentinel lymph node biopsy for breast cancer in British Columbia. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21651836" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |